SCTX · XBRL financial data
Scribe Therapeutics financial statements, every quarter
The same tables from 1 filing, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Revenue from contracts with customers | 1,918 |
| Research and development | 8,823 |
| General and administrative | 2,490 |
| Total operating expenses | 11,313 |
| Operating income (loss) | (9,395) |
| Interest expense | 276 |
| Income tax expense (benefit) | 212 |
| Net income (loss) | (6,477) |
| Earnings per share, basic USD per share | (2.62) |
| Earnings per share, diluted USD per share | (2.62) |
| Weighted average shares, basic thousands of shares | 2,476 |
| Weighted average shares, diluted thousands of shares | 2,476 |
Balance sheet
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Cash and cash equivalents | 35,586 |
| Short-term investments | 7,423 |
| Prepaid and other current assets | 989 |
| Total current assets | 45,105 |
| Property and equipment, net | 5,755 |
| Right-of-use asset | 2,782 |
| Total assets | 57,927 |
| Accounts payable | 2,771 |
| Accrued liabilities | 2,414 |
| Total current liabilities | 78,697 |
| Lease liability, non-current | 4,102 |
| Total liabilities | 102,417 |
| Accumulated deficit | (181,531) |
| Total stockholders' equity | (164,846) |
| Total liabilities and equity | 57,927 |
| Common shares outstanding (cover page) thousands of shares | 18,932 |
Cash flows
CSVFiscal quarters
| In thousands of dollars | Jun 30, 2026 |
|---|---|
| Net income (loss) | (6,477) |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Scribe Therapeutics | 35,586 | 1,918 | not reported | 18.9M | — | 10-QJun 30, 2026 |
| Ocugen | 24,632 | 1,951 | (15,739)* | 339.3M | 5.1 quarters | 10-QSep 30, 2026 |
| Aspira Women's Health | 477 | 17 | (2,010)* | 46.6M | 0.2 quarters | 10-QJun 30, 2026 |
| Healthy Extracts | 190 | 2,067 | 306* | 14.7M | — | 10-QJun 30, 2026 |
| Fate Therapeutics | 32,429 | 2,082 | (23,400) | 119.8M | 6.6 quarters | 10-QJun 30, 2026 |
| Aclaris Therapeutics | 19,167 | 1,629 | (19,847)* | 147.2M | 4.6 quarters | 10-QJun 30, 2026 |
| DBV Technologies | 165,700 | 1,600 | (51,500)* | 314.4M | 3.2 quarters | 10-QSep 30, 2026 |
| Polomar Health Services | 179 | 1,529 | 121* | 28.4M | — | 10-QJun 30, 2026 |
| Caribou Biosciences | 26,194 | 1,499 | (22,787)* | 107.2M | 4.9 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.